RespireRx Pharmaceuticals Inc (RSPI)

[neuroinv]

There wasn't room for two at the top of that program. It illustrates the way that these mergers can disrupt R&D activities--there is no way that his departure will not have some negative impact on the momentum of Pfizer's biotech endeavors. That's not a negative comment on the Wyeth head, who I have not met (I have met Goodman in the past), just a fact-of-life from the merger process. Given the increased BP interest in biologicals, he won't be without Big Pharma employment for long, unless he wants to be.

NeuroInvestment